Zimmer Biomet Holdings, Inc.

ZBH's RSI of 33.8 signals potential oversold conditions in an orthopedic device leader with an $18B market cap, yet the stock trades at a 22.4x P/E that remains above historical orthopedic peer averages. The 6.84% short interest is moderate, suggesting limited squeeze catalyst, while the stock sits meaningfully below its 52-week high—indicating recent selling pressure. The combination of depressed momentum metrics with a valuation that hasn't compressed accordingly suggests either the market is pricing in fundamental deterioration or there's a disconnect between technicals and fundamentals that could create trading friction as oversold bounces face valuation resistance.